Matthew Chivvis spoke to Bloomberg Law about a recent dissent from three Federal Circuit judges, signaling that a potential Supreme Court petition might be on the horizon in Biogen International GmbH v. Mylan Pharmaceuticals Inc., which opened up a new avenue for challenging pharmaceutical patents.
"It's an area where I have alerts set up for every written description precedential opinion coming out because they're so impactful for my clients," Matthew said. "It doesn't matter what side they think they're going to be on. They want to know what's going on here just because it's become the center of a bunch of big decisions recently."
Read the full article (subscription required).
Originally published by Bloomberg Law
Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Morrison & Foerster LLP. All rights reserved
